8-K - InspireMD, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

InspireMD entered a new $75M at-the-market equity offering agreement with BTIG and terminated its prior $75M ATM agreement with Piper Sandler, having sold 1,361,519 shares under the prior program.

Key Takeaways

1Entered Equity Distribution Agreement with BTIG for up to $75,000,000 of common stock in ATM offering.

2BTIG entitled to up to 3.0% commission on gross proceeds.

3Terminated prior Piper EDA effective April 3, 2026 with no penalties.

4Sold 1,361,519 shares under terminated Piper Sandler ATM program.

5Net proceeds for operations, R&D, sales/marketing, working capital.

6Shares issued under S-3 Registration Statement No. 333-286309.

Current Report Details

Event Type

Material Agreement

Other Event

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any offer, solicit

Material Agreement

Source Document

8.01

| Other Events. | |---|---| As previously disclosed, on May 31, 2024, the Company entered into that certain equity distribution agreement (the “ Piper EDA ”) wi

Other Event

$75.0M

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits | Exhibit Number | | Description | |---|---|---| | 5.1 | | Opinion of Greenberg Traurig, LLP | | 1

Exhibits Only

Transaction Details

Material Agreement

Agreement: Equity Distribution Agreement
Parties: InspireMD, Inc., BTIG, LLC

•Offer and sell up to $75,000,000 of common stock ($0.0001 par value)
•At-the-market offering pursuant to Registration Statement on Form S-3 (File No. 333-286309)
•BTIG sales agent with up to 3.0% commission
•Termination of prior Piper Sandler EDA effective April 3, 2026
•Use of proceeds: operations, research and development, sales and marketing, working capital, general corporate purposes

Exhibits (3)

10.1

EX-10.1

5.1

EX-5.1

8-K